Literature DB >> 3325323

Comparison of human and porcine insulin therapies in children with newly diagnosed diabetes mellitus.

K Zuppinger1, C Aebi, S Fankhauser, G Herz, R P Zurbrügg, K Schopfer, T M Neri.   

Abstract

A multicenter, longitudinal study of children below the age of 16 years with newly diagnosed Type 1 (insulin-dependent) diabetes treated either with porcine monocomponent insulin (n = 26) or semisynthetic human monocomponent insulin (n = 26) was performed during the first 24 months after onset of diabetes. The two groups were carefully matched for age, duration of disease symptoms, initial metabolic values, islet cell antibodies and HLA-DR antigens. During the 24-month observation period there was no significant difference between the two groups in respect to the clinical course, insulin dosage, HbA1 and residual B-cell activity. No child in either group had a real remission without necessitating insulin therapy. The prevalence of insulin antibodies increased slowly and was 62% in the group treated by human insulin and 52% in the porcine insulin-treated group after 24 months. The titres were generally low and there was no statistical difference between the two groups in respect to insulin antibody formation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3325323     DOI: 10.1007/bf00295873

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

1.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

2.  Radioimmunoelectrophoresis in the determination of insulin binding to IgG.

Authors:  A H Christiansen
Journal:  Horm Metab Res       Date:  1973-05       Impact factor: 2.936

3.  [On radio-immunologic determination of insulin in blood].

Authors:  F Melani; H Ditschuneit; K M Bartelt; H Friedrich; E F Pfeiffer
Journal:  Klin Wochenschr       Date:  1965-09-15

4.  Insulin antibodies in the serum of diabetic children treated from the diagnosis of the disease with highly purified insulins.

Authors:  H K Akerblom; A L Mäkelä
Journal:  Acta Paediatr Scand Suppl       Date:  1977

5.  [Clinical experiences with the substitution of biosynthetic human insulin in children and adolescents with type I diabetes].

Authors:  P Hürter; W von Schütz; R Zick; K Stolzenbach
Journal:  Monatsschr Kinderheilkd       Date:  1985-05       Impact factor: 0.323

6.  Immunogenicity of monocomponent human and porcine insulin in newly diagnosed type 1 (insulin-dependent) diabetic children.

Authors:  L G Heding; M O Marshall; B Persson; G Dahlquist; B Thalme; F Lindgren; H K Akerblom; A Rilva; M Knip; J Ludvigsson
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

7.  Insulin antibodies in diabetic children treated with monocomponent porcine insulin from the onset: relationship to B-cell function and partial remission.

Authors:  J Ludvigsson
Journal:  Diabetologia       Date:  1984-02       Impact factor: 10.122

8.  Comparison of human versus porcine insulin in treatment of diabetes in children.

Authors:  S A Greene; M A Smith; B Cartwright; J D Baum
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-26

9.  Human insulin and porcine insulin in the treatment of diabetic children: comparison of metabolic control and insulin antibody production.

Authors:  N P Mann; D I Johnston; W G Reeves; M A Murphy
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-26

10.  A prospective study of the immunogenicity of porcine insulin in HLA-typed new insulin-treated diabetics.

Authors:  L O Almér; G Ekberg; S Fankhauser; P D Home; R Worth; S Sailer; A B Kurtz; M Christy
Journal:  Diabetes Res       Date:  1985-09
View more
  2 in total

1.  The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model.

Authors:  J L Ottesen; P Nilsson; J Jami; D Weilguny; M Dührkop; D Bucchini; S Havelund; J M Fogh
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

Review 2.  Engineering of therapeutic proteins production in Escherichia coli.

Authors:  Mariusz Kamionka
Journal:  Curr Pharm Biotechnol       Date:  2011-02-01       Impact factor: 2.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.